DPT vaccine evolution: Formulation differences, standardisation issues, and development prospects

DPT vaccine evolution: Formulation differences, standardisation issues, and development prospects

INTRODUCTION. Currently, diphtheria, pertussis, and tetanus (DTP) vaccines are available in tetra-, penta-, and hexavalent combinations with inactivated poliomyelitis, Haemophilus influenzae, and hepatitis B components. Despite the widespread introduction of DTP vaccines in national vaccination prog...

Full description

Saved in:

Bibliographic Details
Main Authors:	E. I. Komarovskaya, O. V. Proskurina, A. A. Soldatov
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2025-04-01
Series:	Биопрепараты: Профилактика, диагностика, лечение
Subjects:	diphtheria vaccine tetanus vaccine pertussis vaccine acellular pertussis vaccine whole-cell pertussis vaccine dpt vaccine preventive vaccination vaccination immunity combination vaccines national vaccination schedule
Online Access:	https://www.biopreparations.ru/jour/article/view/671
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

TOLERANCE OF CHILDREN OLDER THAN 4 YEARS TO ACELLULAR DPT-VACCINES: RESULTS OF A RETROSPECTIVE STUDY
by: A. G. Gaivoronskaya, et al.
Published: (2017-02-01)

PERTUSSIS IS COMING BACK? IMPROVEMENT OF FORGOTTEN CHILDHOOD INFECTION CONTROL
by: M. V. Fedoseenko, et al.
Published: (2012-04-01)

How to improve pertussis vaccination in pregnancy: a European expert review
by: Adam Finn, et al.
Published: (2025-12-01)

Assessment of the timeliness of vaccination against pertussis in children of the first year of life and the reasons for the violation of the vaccination schedule
by: T. M. Chernova, et al.
Published: (2021-07-01)

Incidence of vaccine preventable diseases in pediatric population of Latvia
by: Renāta Klagiša, et al.
Published: (2016-06-01)

A Clinical Study of the Safety and Tolerability of Live Nasal Vaccines for the Prevention of Pertussis
by: A. Yu. Medkova, et al.
Published: (2021-02-01)

Analysis of strategies China should adopt in response to global pertussis trends
by: Shuying Jiang, et al.
Published: (2025-12-01)

Safety of Combination Vaccines with Whole Cell Pertussis Component
by: O. V. Perelygina, et al.
Published: (2016-12-01)

The interdisciplinary Meeting of Experts’s Resolution «Unresolved Questions of Pertussis Epidemiology in the Russian Federation and the New Possibilities for Vaccination»
by: Article Editorial
Published: (2018-09-01)

Safety of pertussis vaccines for adolescents
by: M. P. Kostinov, et al.
Published: (2020-10-01)

Estimation of Consistency of Production of the Pertussis Component of DTP Vaccine in Terms of Immunogenic Activity and Specific Safety Using Shewhart Charts
by: I. A. Alekseeva, et al.
Published: (2018-12-01)

Development of a Method and a Scheme for the Use of a Live Recombinant Vaccine "GamLPV". Safety and Tolerability of Double Intranasal Vaccination of Healthy Adult Volunteers
by: G. I. Karataev, et al.
Published: (2022-09-01)

PERTUSSIS — INFECTION NOT UNDER COMPLETE CONTROL
by: V. K. Tatochenko
Published: (2014-03-01)

Pertussis vaccination: problems, possible solutions
by: S. M. Kharit, et al.
Published: (2020-06-01)

Pertussis vaccination in adults: a behavioral study of physicians from the US, France, and Germany
by: Donald Middleton, et al.
Published: (2024-11-01)

Innovative adjuvant strategies for next-generation pertussis vaccines
by: Ge Yu, et al.
Published: (2025-12-01)

Vaccination in Chronic Obstructive Pulmonary Disease
by: Wang-Chun Kwok, et al.
Published: (2025-02-01)

The timely vaccination rate of pertussis-containing vaccines among children born in Henan province from 2012 to 2021: a surveillance data analysis
by: Changshuang WANG, et al.
Published: (2025-06-01)

Enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in eastern China during the COVID-19 pandemic
by: Hinpetch Daungsupawong, et al.
Published: (2024-12-01)

Pertussis vaccine effectiveness following country-wide implementation of a hexavalent acellular pertussis immunization schedule in infants and children in Panama
by: Arlene E. Calvo, et al.
Published: (2024-12-01)

Pertussis in the Voronezh Region: Epidemiology and Vaccination
by: N. P. Mamchik, et al.
Published: (2020-05-01)

Antibody avidity to pertussis toxin after acellular pertussis vaccination and infection
by: Aapo Knuutila, et al.
Published: (2023-12-01)

A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b invasive infections (DTaP-IPV/Hib) in South Korean infants
by: Diego Mpia Elenge, et al.
Published: (2024-12-01)

Pertactin deficiency of Bordetella pertussis: Insights into epidemiology, and perspectives on surveillance and public health impact
by: Ulrich Heininger, et al.
Published: (2024-12-01)

Immunogenicity of GamLPV, an intranasal live vaccine for pertussis prevention, in adult volunteers: a blind, randomised, placebo-controlled trial to optimise the method and schedule of administration
by: A. A. Lidzhieva, et al.
Published: (2025-04-01)

Critical Pertussis: “Prevention is better than cure”
by: T M Jayashree, et al.
Published: (2024-10-01)

Analysis of the morbidity and the coverage of vaccination against pertussis level in Zaporozhye Region
by: O. V. Konakova, et al.
Published: (2013-08-01)

Influence of storage conditions on the toxicity of whole-cell pertussis vaccine in outbred mice
by: I. A. Alekseeva, et al.
Published: (2025-04-01)

Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America
by: María L. Ávila-Agüero, et al.
Published: (2025-12-01)

Prevalence of Pertactin-Deficient Bordetella pertussis Isolates, Slovenia
by: Alex-Mikael Barkoff, et al.
Published: (2024-11-01)

Seroprevalence of tetanus and pertussis antibodies among health care workers in Wuhu, China
by: Wei Shi, et al.
Published: (2024-12-01)

Risk of Brain Damage Following Pertussis Immunization with Whole-Cell cf Acellular Vaccines
by: J Gordon Millichap
Published: (2004-06-01)

Pertussis epidemiological surveillance and immunization history in children under five years in a megacity in China from 2019 to 2023
by: Yang Liu, et al.
Published: (2025-12-01)

Impact of the COVID-19 pandemic on the timeliness of pertussis-containing vaccination: A cohort study in Shanghai, China
by: Zhuoying Huang, et al.
Published: (2025-12-01)

Adenoviral-vectored vaccine against Bordetella pertussis fimbrial antigen induces partial protection in a mouse model
by: Alexa Dierig, et al.
Published: (2025-06-01)

Pertussis in Children in an Era of Vaccination
by: Alison Marion Snodgrass, et al.
Published: (2019-01-01)

Antibody signatures elicited by potent and subpotent whole-cell pertussis vaccines in mice
by: Yetunde Adewunmi, et al.
Published: (2025-05-01)

Economic burden of pertussis in children: A single-center analysis in Hangzhou, China
by: Yan Liu, et al.
Published: (2024-12-01)

Post-Vaccination Immunity to Pertussis in Children of Lipetsk, New Management Capabilitiesto Infection
by: T. V. Timofeeva, et al.
Published: (2019-06-01)

Evaluation of acellular pertussis vaccine: comparisons among different strains of mice
by: Jie Wei, et al.
Published: (2023-12-01)